Relyvrio Side Effects
Generic name: sodium phenylbutyrate / taurursodiol
Medically reviewed by Drugs.com. Last updated on May 6, 2024.
Note: This document contains side effect information about sodium phenylbutyrate / taurursodiol. Some dosage forms listed on this page may not apply to the brand name Relyvrio.
Applies to sodium phenylbutyrate / taurursodiol: oral powder for suspension.
Serious side effects of Relyvrio
Along with its needed effects, sodium phenylbutyrate/taurursodiol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking sodium phenylbutyrate / taurursodiol:
More common
Other side effects of Relyvrio
Some side effects of sodium phenylbutyrate / taurursodiol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Body aches or pain
- chills
- cough
- ear congestion
- fever
- headache
- loss of voice
- sneezing
- sore throat
- stuffy or runny nose
- trouble breathing
- unusual tiredness or weakness
For Healthcare Professionals
Applies to sodium phenylbutyrate / taurursodiol: oral powder for reconstitution.
Gastrointestinal
Very common (10% or more): Abdominal pain (21%), diarrhea (25%), nausea (18%), salivary hypersecretion (11%)[Ref]
General
The most common adverse reactions were diarrhea, abdominal pain, nausea, and upper respiratory tract infection. While gastrointestinal side effects occurred throughout the study duration, they were more common in the first three weeks of treatment.[Ref]
Nervous system
Common (1% to 10%): Dizziness[Ref]
Other
Very common (10% or more): Fatigue (12%)[Ref]
Respiratory
Very common (10% or more): Upper respiratory tract infection (18%)[Ref]
More about Relyvrio (sodium phenylbutyrate / taurursodiol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous central nervous system agents
- En español
Patient resources
Professional resources
Related treatment guides
References
1. (2022) "Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol)." Amylyx Pharmaceuticals, 1
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.